Navigation Links
Study: Robot-assisted surgery for prostate cancer controls the disease for 10 years
Date:7/16/2014

DETROIT Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital.

The study also suggested that traditional methods of measuring the severity and possible spread of the cancer together with molecular techniques might, with further research, help to create personalized, cost-effective treatment regimens for prostate cancer patients who undergo the surgical procedure.

The findings apply to men whose cancer has not spread beyond the prostate, and the results are comparable to the well-established and more invasive open surgery to remove the entire diseased prostate and some surrounding tissue.

The research study is published this month online in European Urology, the official journal of the European Association of Urology.

"Until our analysis, there was little available information on the long-term oncologic outcomes for patients who undergo robot-assisted radical prostatectomy, or RARP," says Mireya Diaz, Ph.D., Director of Biostatistics at the Henry Ford's Vattikuti Urology Institute (VUI) and lead author of the study.

"As one of the very first hospitals to establish a structured RARP program a little over a decade ago, we were able to determine the long-term effectiveness of the technique thanks to the continued feedback of our patients and the follow-up efforts of the VUI team," Dr. Diaz adds.

The researchers followed 483 consecutive men who had cancer that had not spread outside the prostate and received RARP as their first treatment. All cases were from 2001 to 2003, the earliest years of Henry Ford's robot-assisted prostate surgery program.

Using several standard measures of cancer-treatment success including biochemical markers of recurrence, incidence of metastasis or the spread of cancer beyond the prostate, and cancer-specific survival the researchers found that 98.8 percent of the patients survived cancer for 10 years after their surgery.

Further analysis showed that the severity of the cancer after RARP was the best predictor of a recurrence, and the level of prostate-specific antigen, or PSA, in the bloodstream which is now routinely measured as a test for the possible presence of prostate cancer can be combined with severity to determine future treatment.

"Disease severity and postoperative PSA measurements can guide physicians in identifying the varying levels of cancer recurrence risk," Dr. Diaz explains. "This includes those patients who can best benefit from secondary treatment as well as long-term monitoring."

The study suggests that persistent PSA levels after RARP signals the risk that cancer may progress and soon require a second or salvage treatment of another kind. Lower risk patients after RARP warrant careful monitoring within five years after surgery and more protracted later, while those at higher risk may need follow-up monitoring beyond 10 years.
'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-876-8709
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
2. Study: Insomnia takes toll on tinnitus patients
3. Study: No link between depression, nasal obstruction
4. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
5. Study: Kids Who Sleep in Parents Bed Less Likely to Be Overweight
6. OHSU study: Misdiagnosis of MS is costing health system millions per year
7. UW study: Sleep apnea associated with higher mortality from cancer
8. Study: Heart damage after chemo linked to stress in cardiac cells
9. STeleR study: Telerehab improves functioning after stroke
10. Study: Willingness to be screened for dementia varies by age but not by sex, race or income
11. Study: 21 percent of newly admitted nursing home residents sustain a fall during their stay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... A new ... of movement to motion capture, all by utilizing a common Wi-Fi network and a ... to transmit data from any location with Wi-Fi, and use a mobile device to ...
(Date:5/25/2016)... ... ... time when tampons and pads were the only options for women for period protection. But ... Lunette . To make that time of the month less of a pain and more ... , It’s easy to see why Lunette is so popular. Lunette cups are eco-friendly, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Dr. Travis Schwarz is an experienced dentist ... Road, O’Fallon, MO 63366. He serves patients of all ages with a full menu ... Schwarz’s success is reflected in the superior patient reviews that he has consistently earned ...
(Date:5/25/2016)... ... May 25, 2016 , ... DKT International, one ... developing world, is pleased to release their 2015 global impact data. In 2015, ... almost 14,000 maternal deaths and 3.8 million unsafe abortions across 21 countries worldwide. ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... of its annual Medical and Prescription Drug survey , an employee ... The survey, which was conducted in December 2015, indicates that employers are turning ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... SPRINGS, Florida , May 25, 2016 ... Business Conference & Expo earlier this month, the numbers ... As revenues continue to climb into the billions, more ... the newly released 4th Edition State of Legal Marijuana ... Frontier, a cannabis-focused data-analysis firm, much of the increase ...
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
Breaking Medicine Technology: